SELLAS Life Sciences (SLS) Current Assets (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Current Assets of $111.2 million for Q1 2026, up 247.7% year-over-year from $32.0 million in Q1 2025, and up 47.81% quarter-over-quarter from $75.2 million in Q4 2025.
SELLAS Life Sciences (SLS) Current Assets (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Current Assets for 17 consecutive years, with $111.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 247.7% year-over-year to $111.2 million; the TTM figure through Mar 2026 stood at $111.2 million (up 247.7% YoY), while the FY2025 annual figure was $75.2 million, up 360.65% from the prior year.
- Current Assets improved to $111.2 million in Q1 2026 per SLS's latest filing, from $75.2 million in the prior quarter.
- Across five years, Current Assets topped out at $111.2 million in Q1 2026 and bottomed at $3.2 million in Q4 2023.
- Historically, Current Assets has averaged $29.9 million across 5 years, with a median of $22.6 million in 2022.
- Annual changes were most pronounced in 2023 — Current Assets sank 82.14% — and 2024, when it soared 414.72%.
- SELLAS Life Sciences' Current Assets stood at $17.8 million in 2022, then plunged by 82.14% to $3.2 million in 2023, then jumped by 414.72% to $16.3 million in 2024, then jumped by 360.65% to $75.2 million in 2025, then jumped by 47.81% to $111.2 million in 2026.
- Business Quant data shows SLS's Current Assets at $111.2 million in Q1 2026, $75.2 million in Q4 2025, and $49.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | 142.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 142.51 Mn |
| Mar 31, 2026 | 111.17 Mn |
| Dec 31, 2025 | 75.21 Mn |
| Sep 30, 2025 | 49.05 Mn |
| Jun 30, 2025 | 29.45 Mn |
| Mar 31, 2025 | 31.97 Mn |
| Dec 31, 2024 | 16.33 Mn |
| Sep 30, 2024 | 24.04 Mn |
| Jun 30, 2024 | 12.30 Mn |
| Mar 31, 2024 | 21.50 Mn |
| Dec 31, 2023 | 3.17 Mn |
| Sep 30, 2023 | 5.20 Mn |
| Jun 30, 2023 | 15.58 Mn |
| Mar 31, 2023 | 26.02 Mn |
| Dec 31, 2022 | 17.76 Mn |
| Sep 30, 2022 | 22.61 Mn |
| Jun 30, 2022 | 28.74 Mn |
| Mar 31, 2022 | 17.84 Mn |
| Dec 31, 2021 | 23.04 Mn |
| Sep 30, 2021 | 28.97 Mn |